Review of the many faces of synthetic cannabinoid toxicities
- PMID: 30842917
- PMCID: PMC6398358
- DOI: 10.9740/mhc.2019.03.093
Review of the many faces of synthetic cannabinoid toxicities
Abstract
Introduction: Synthetic cannabinoids (SCs) are psychoactive substances that are gaining popularity for their availability and lack of detection by standardized drug tests. Although some users may perceive SCs as safer alternatives to marijuana, some SCs are more potent and result in more severe toxicities.
Methods: A search of the literature was conducted in the PubMed and SciFinder databases. Results in PubMed were limited to human studies, and only articles in English were included.
Results: Review of the literature illustrates the hazards associated with SC use. A range of severe toxicities affecting numerous systems has been identified, such as arrhythmias, myocardial infarction, sudden cardiac death, psychosis, suicidal ideation, seizures, acute tubular necrosis, and intracranial hemorrhage. Additionally, a recent outbreak of coagulopathies and at least 4 associated deaths due to SCs tainted with brodifacoum have been reported.
Discussion: Synthetic cannabinoids may be perceived as a safer alternative to marijuana; however, SCs can be more potent at the cannabinoid receptors and in turn have greater toxicities. Limited information is available on the metabolism of SCs; however, cytochrome P450 pathways may be involved, which could result in drug interactions and unpredicted adverse effects. Toxicity with SC use is not just related to its effects, but also to additives that may taint these products and enhance their effects. Health care providers should be aware of the range of toxicities related to SC use, and tainted products such as these agents are not detected on routine drug screens.
Keywords: K2; bleeding; cannabinoids; designer drugs; hemorrhage; spice; street drugs; synthetic cannabinoids; synthetic cannabis; synthetic marijuana; toxicity.
Conflict of interest statement
Disclosures: The authors of this article have no conflicts of interest to disclose.
References
-
- Shanks KG, Clark W, Behonick G. Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol. 2016;40(3):236–9. doi: 10.1093/jat/bkv142. 26755539 PMC4885918 DOI: 10.1093/jat/bkv142 PubMed PMID: 26755539 PubMed Central PMCID: PubMed PMID: 26755539 PubMed Central PMCID: PMC4885918. - DOI - PMC - PubMed
-
- Abouchedid R, Ho JH, Hudson S, Dines A, Archer JRH, Wood DM, et al. Acute toxicity associated with use of 5F-derivations of synthetic cannabinoid receptor agonists with analytical confirmation. J Med Toxicol. 2016;12(4):396–401. doi: 10.1007/s13181-016-0571-7. 27456262 PMC5135680 DOI: 10.1007/s13181-016-0571-7 PubMed PMID: 27456262 PubMed Central PMCID: PubMed PMID: 27456262 PubMed Central PMCID: PMC5135680. - DOI - PMC - PubMed
-
- Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol. 2015;34(5):557–60. doi: 10.1177/0960327114550886. 25233895 DOI: 10.1177/0960327114550886 PubMed PMID: PubMed PMID: 25233895. - DOI - PubMed
-
- Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54(1):1–13. doi: 10.3109/15563650.2015.1110590. 26567470 DOI: 10.3109/15563650.2015.1110590 PubMed PMID: PubMed PMID: 26567470. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources